Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia

Br J Haematol. 2021 Sep;194(5):927-931. doi: 10.1111/bjh.17573. Epub 2021 Jun 7.
No abstract available

Keywords: Keywords: acute myeloid leukaemia; acute myeloid leukemia; differentiation; differentiation.; haematopoietic cell transplant; hematopoietic cell transplant; isocitrate dehydrogenase inhibitor.

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Cell Differentiation / drug effects
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Graft vs Host Disease / etiology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Isocitrate Dehydrogenase / antagonists & inhibitors*
  • Isocitrate Dehydrogenase / genetics
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy*
  • Middle Aged
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy
  • Transplantation, Homologous / adverse effects

Substances

  • Enzyme Inhibitors
  • Isocitrate Dehydrogenase